Compare AURE & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AURE | ASRT |
|---|---|---|
| Founded | 2018 | 1995 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.5M | 75.1M |
| IPO Year | N/A | 1997 |
| Metric | AURE | ASRT |
|---|---|---|
| Price | $0.30 | $11.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 1.1M | 70.3K |
| Earning Date | 01-06-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,785,569.00 | ★ $137,354,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 434.30 | 9.22 |
| 52 Week Low | $0.23 | $7.71 |
| 52 Week High | $2.70 | $15.15 |
| Indicator | AURE | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 44.01 | 81.67 |
| Support Level | $0.24 | $11.08 |
| Resistance Level | $0.32 | $12.54 |
| Average True Range (ATR) | 0.04 | 0.68 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 69.77 | 84.72 |
Aurelion Inc is engaged in providing private wealth management and asset management services to high-net-worth and ultra-high-net-worth individuals by identifying and purchasing well-matched wealth management products offered by third-party providers. Its subsidiary operates a wealth management business that works with licensed product brokers in Hong Kong, currently consisting solely of insurance brokers distributing insurance products, and assists in customizing wealth management investment portfolios for clients. The Company generates revenue for its subsidiaries' wealth management business from product brokers in the form of referral fees, which are calculated based on the value of wealth management products purchased by clients from such brokers.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.